S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:GLYC

GlycoMimetics - GLYC Price Target & Analyst Ratings

$0.83
-0.02 (-2.34%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.83
$0.88
50-Day Range
$0.54
$0.90
52-Week Range
$0.51
$2.50
Volume
116,570 shs
Average Volume
187,454 shs
Market Capitalization
$43.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

GlycoMimetics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$8.50
919.18% Upside
High Prediction$13.00
Average Prediction$8.50
Low Prediction$4.00
TypeCurrent
8/18/21 to 8/18/22
1 Month Ago
7/19/21 to 7/19/22
3 Months Ago
5/20/21 to 5/20/22
1 Year Ago
8/18/20 to 8/18/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.50$4.00$4.00$12.00
Predicted Upside919.18% Upside97.04% Upside97.04% Upside287.72% Upside
Get GlycoMimetics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.


GLYC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GLYC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GlycoMimetics Stock vs. The Competition

TypeGlycoMimeticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyBuyHold
Predicted Upside900.00% Upside880.53% Upside14.61% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
310
66.81%
Underperform Votes
154
33.19%
Avg. Outperform Votes
168
66.93%
Avg. Underperform Votes
83
33.07%
Avg. Outperform Votes
854
68.54%
Avg. Underperform Votes
392
31.46%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/4/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$14.00 ➝ $13.00+1,755.26%
11/12/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$3.00 ➝ $4.00+97.04%
5/3/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$8.00 ➝ $9.00+276.57%
12/8/2020Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Buy$9.00 ➝ $15.00+294.74%
3/27/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boris Peaker
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
11/7/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$6.00 ➝ $5.00-15.68%
(Data available from 8/18/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GLYC Price Target - Frequently Asked Questions

What is GlycoMimetics's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for GlycoMimetics stock is Buy based on the current 2 buy ratings for GLYC. The average twelve-month price prediction for GlycoMimetics is $8.50 with a high price target of $13.00 and a low price target of $4.00. Learn more on GLYC's analyst rating history.

Do Wall Street analysts like GlycoMimetics more than its competitors?

Analysts like GlycoMimetics more than other Medical companies. The consensus rating score for GlycoMimetics is 3.00 while the average consensus rating score for medical companies is 2.70. Learn more on how GLYC compares to other companies.

Do MarketBeat users like GlycoMimetics more than its competitors?

MarketBeat users like GlycoMimetics more than other Medical companies. 66.81% of MarketBeat users gave GlycoMimetics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does GlycoMimetics's stock price have much upside?

According to analysts, GlycoMimetics's stock has a predicted upside of 522.55% based on their 12-month price targets.

What analysts cover GlycoMimetics?

GlycoMimetics has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GLYC) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.